Evidence map›Paper›PMID 36067041›Full record

ArticleAmerican journal of respiratory cell and molecular biology2023

Targeted Inhibition of Select Extracellular Signal-regulated Kinases 1 and 2 Functions Mitigates Pathological Features of Asthma in Mice.

Sushrut D Shah, Ajay P Nayak, Pawan Sharma, Dominic R Villalba, Sankar Addya, Weiliang Huang, Paul Shapiro, Maureen A Kane, Deepak A Deshpande

Open access · greenAbstract read
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Agonist-specific conformational dynamics at the βBritish journal of pharmacology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Carbon dioxide and MAPK signalling: towards therapy for inflammation.Cell communication and signaling : CCS · 2023
    Review
  7. Article
  8. Selective Inhibition of Extracellular Signal-regulated Kinases 1 and 2: When Less Is More.American journal of respiratory cell and molecular biology · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sushrut D ShahCenter for Translational Medicine, Jane and Leonard Korman Lung Center, and.ORCID 0000-0002-4201-6532
Ajay P NayakCenter for Translational Medicine, Jane and Leonard Korman Lung Center, and.ORCID 0000-0003-3437-0096
Pawan SharmaCenter for Translational Medicine, Jane and Leonard Korman Lung Center, and.ORCID 0000-0002-2904-2306
Dominic R VillalbaCenter for Translational Medicine, Jane and Leonard Korman Lung Center, and.
Sankar AddyaSidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania; and.
Weiliang HuangDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Baltimore, Maryland.
Paul ShapiroDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Baltimore, Maryland.
Maureen A KaneDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Baltimore, Maryland.
Deepak A DeshpandeCenter for Translational Medicine, Jane and Leonard Korman Lung Center, and.
University of Maryland, Baltimore · USThomas Jefferson University · US

Funding

E3 ubiquitin ligase RNF145 in airway smooth muscle functions and in asthmaR01HL161205 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI Pawan Sharma · 2022 to 2026
$2.4M
tRNA-derived non-coding RNAs in ASM function and in asthmaR01HL150560 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI DESHPANDE, DEEPAK A, KIRINO, YOHEI · 2020 to 2023
$2.4M
Functional Diversity of Compartmentalized Calcium Signaling in Airway Smooth MuscleR01HL137030 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI DESHPANDE, DEEPAK A · 2018 to 2021
$2.2M
Mitochondrial translocator protein: a target for bronchodilationR01HL153602 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI NAYAK, AJAY · 2021 to 2025
$2.0M
Evaluation of novel substrate specific inhibitors of ERK1/2 in the treatment of asthmaR21AI126492 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI DESHPANDE, DEEPAK A, SHAPIRO, PAUL S · 2016 to 2017
$440k
NHLBI NIH HHS R01 HL137030NHLBI NIH HHS R01 HL150560NHLBI NIH HHS R01 HL153602NHLBI NIH HHS R01 HL161205NIAID NIH HHS R21 AI126492
6 · The paper itself

Abstract

ERK1/2 (extracellular signal-regulated kinases 1 and 2) regulate the activity of various transcription factors that contribute to asthma pathogenesis. Although an attractive drug target, broadly inhibiting ERK1/2 is challenging because of unwanted cellular toxicities. We have identified small molecule inhibitors with a benzenesulfonate scaffold that selectively inhibit ERK1/2-mediated activation of AP-1 (activator protein-1). Herein, we describe the findings of targeting ERK1/2-mediated substrate-specific signaling with the small molecule inhibitor SF-3-030 in a murine model of house dust mite (HDM)-induced asthma. In 8- to 10-week-old BALB/c mice, allergic asthma was established by repeated intranasal HDM (25 μg/mouse) instillation for 3 weeks (5 days/week). A subgroup of mice was prophylactically dosed with 10 mg/kg SF-3-030/DMSO intranasally 30 minutes before the HDM challenge. Following the dosing schedule, mice were evaluated for alterations in airway mechanics, inflammation, and markers of airway remodeling. SF-3-030 treatment significantly attenuated HDM-induced elevation of distinct inflammatory cell types and cytokine concentrations in BAL and IgE concentrations in the lungs. Histopathological analysis of lung tissue sections revealed diminished HDM-induced pleocellular peribronchial inflammation, mucus cell metaplasia, collagen accumulation, thickening of airway smooth muscle mass, and expression of markers of cell proliferation (Ki-67 and cyclin D1) in mice treated with SF-3-030. Furthermore, SF-3-030 treatment attenuated HDM-induced airway hyperresponsiveness in mice. Finally, mechanistic studies using transcriptome and proteome analyses suggest inhibition of HDM-induced genes involved in inflammation, cell proliferation, and tissue remodeling by SF-3-030. These preclinical findings demonstrate that function-selective inhibition of ERK1/2 signaling mitigates multiple features of asthma in a murine model.

Indexed as

AsthmaAnimalsDisease Models, AnimalExtracellular Signal-Regulated MAP KinasesInflammationLungMiceMice, Inbred BALB CMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3PyroglyphidaeExtracellular Signal-Regulated MAP KinasesMapk1 protein, mouseMapk3 protein, mouseMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3AP-1asthmaERK1/2HDMSF-3–030

Identifiers

PMID36067041
PMCPMC9817918
OpenAlexW4294843027

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.